Clinical and phenotypic characteristics according to MYC and BCL2 genetic alterations
| Characteristic . | MYC mutation . | p . | MYC Gain/AMP . | P . | MYC translocation . | P . | BCL2 mutation . | P . | BCL2 Gain/AMP . | P . | BCL2 translocation . | P . | MYC/BCL2 DHIT . | P . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes (n = 29) n (%) . | No (n = 318) n (%) . | Yes (n = 69) n (%) . | No (n = 269) n (%) . | Yes (n = 50) n (%) . | No (n = 275) n (%) . | Yes (n = 87) n (%) . | No (n = 260) n (%) . | Yes (n = 85) n (%) . | No (n = 253) n (%) . | Yes (n = 90) n (%) . | No (n = 210) n (%) . | Yes (n = 25) n (%) . | No (n = 272) n (%) . | ||||||||
| Age | |||||||||||||||||||||
| >60 y | 18 (62) | 187 (59) | .73 | 40 (58) | 161 (60) | .77 | 35 (70) | 159 (58) | .11 | 55 (62) | 150 (58) | .45 | 61 (72) | 140 (55) | .008 | 59 (66) | 119 (57) | .15 | 16 (61) | 161 (59) | .82 |
| Sex | |||||||||||||||||||||
| Male | 16 (55) | 202 (63) | .37 | 48 (70) | 163 (61) | .17 | 33 (66) | 169 (61) | .54 | 46 (52) | 172 (66) | .018 | 56 (66) | 155 (61) | .45 | 51 (57) | 136 (65) | .19 | 16 (61) | 169 (62) | .95 |
| Stage | |||||||||||||||||||||
| III, IV | 17 (59) | 167 (53) | .59 | 41 (60) | 139 (53) | .25 | 25 (53) | 145 (53) | .95 | 46 (52) | 138 (54) | .74 | 50 (61) | 130 (52) | .15 | 52 (58) | 110 (53) | .38 | 14 (56) | 147 (54) | .88 |
| LDH | |||||||||||||||||||||
| >ULN | 17 (61) | 148 (51) | .35 | 35 (60) | 126 (50) | .17 | 28 (67) | 127 (49) | .038 | 48 (61) | 117 (49) | .079 | 39 (51) | 122 (53) | .85 | 47 (57) | 96 (49) | .23 | 13 (59) | 129 (51) | .47 |
| ECOG PS | |||||||||||||||||||||
| 2 or more | 12 (41) | 102 (32) | .33 | 22 (32) | 89 (33) | .86 | 17 (36) | 86 (31) | .51 | 35 (40) | 79 (31) | .13 | 27 (33) | 84 (33) | .88 | 36 (40) | 58 (28) | .033 | 9 (36) | 84 (31) | .62 |
| Extranodal sites | |||||||||||||||||||||
| 2 or more | 6 (21) | 50 (16) | .51 | 10 (15) | 42 (16) | .82 | 5 (11) | 45 (16) | .32 | 13 (15) | 43 (17) | .64 | 11 (13) | 41 (16) | .53 | 9 (10) | 37 (18) | .094 | 1 (4) | 45 (17) | .095 |
| IPI score | .22 | .60 | .34 | .40 | .33 | .071 | .86 | ||||||||||||||
| Low (0-1) | 10 (35) | 102 (34) | 19 (29) | 89 (35) | 13 (30) | 95 (36) | 24 (28) | 88 (36) | 24 (30) | 84 (35) | 21 (24) | 77 (38) | 7 (30) | 91 (35) | |||||||
| Intermediate (2-3) | 10 (35) | 143 (48) | 34 (52) | 117 (45) | 19 (43) | 124 (47) | 44 (52) | 109 (45) | 35 (44) | 116 (48) | 47 (54) | 89 (44) | 12 (52) | 122 (46) | |||||||
| High (4-5) | 9 (30) | 56 (19) | 12 (19) | 51 (20) | 12 (27) | 48 (18) | 17 (22) | 48 (19) | 20 (26) | 43 (17) | 19 (22) | 36 (18) | 4 (17) | 51 (19) | |||||||
| Cell of origin* | .088 | .001 | .047 | <.001 | <.001 | <.001 | <.001 | ||||||||||||||
| ABC | 5 (19) | 99 (34) | 11 (17) | 87 (35) | 11 (22) | 92 (35) | 10 (12) | 94 (39) | 46 (58) | 52 (22) | 6 (7) | 89 (43) | 0 | 93 (35) | |||||||
| GCB | 19 (73) | 164 (55) | 48 (74) | 132 (53) | 35 (71) | 142 (53) | 66 (80) | 117 (49) | 24 (30) | 156 (66) | 78 (88) | 98 (47) | 25 (100) | 140 (53) | |||||||
| Unclassified | 2 (8) | 34 (11) | 6 (9) | 30 (12) | 3 (6) | 32 (12) | 7 (8) | 29 (12) | 9 (11) | 27 (12) | 5 (5) | 21 (10) | 0 | 31 (12) | |||||||
| MYC IHC | |||||||||||||||||||||
| Positive | 17 (63) | 117 (39) | .015 | 33 (51) | 98 (39) | .079 | 36 (73) | 96 (36) | <.001 | 30 (37) | 104 (42) | .35 | 44 (54) | 87 (37) | .005 | 38 (44) | 88 (42) | .82 | 20 (80) | 105 (39) | <.001 |
| BCL2 IHC | |||||||||||||||||||||
| Positive | 18 (67) | 199 (67) | .99 | 45 (69) | 164 (65) | .53 | 38 (78) | 172 (64) | .064 | 65 (80) | 152 (62) | .003 | 69 (86) | 140 (59) | <.001 | 80 (91) | 115 (56) | <.001 | 23 (92) | 170 (64) | .004 |
| MYC/BCL2 IHC | |||||||||||||||||||||
| DPE | 15 (56) | 85 (28) | .004 | 23 (35) | 74 (30) | .36 | 30 (61) | 68 (25) | <.001 | 26 (32) | 74 (30) | .70 | 41 (51) | 56 (24) | <.001 | 33 (38) | 61 (30) | .16 | 18 (72) | 75 (28) | <.001 |
| Characteristic . | MYC mutation . | p . | MYC Gain/AMP . | P . | MYC translocation . | P . | BCL2 mutation . | P . | BCL2 Gain/AMP . | P . | BCL2 translocation . | P . | MYC/BCL2 DHIT . | P . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes (n = 29) n (%) . | No (n = 318) n (%) . | Yes (n = 69) n (%) . | No (n = 269) n (%) . | Yes (n = 50) n (%) . | No (n = 275) n (%) . | Yes (n = 87) n (%) . | No (n = 260) n (%) . | Yes (n = 85) n (%) . | No (n = 253) n (%) . | Yes (n = 90) n (%) . | No (n = 210) n (%) . | Yes (n = 25) n (%) . | No (n = 272) n (%) . | ||||||||
| Age | |||||||||||||||||||||
| >60 y | 18 (62) | 187 (59) | .73 | 40 (58) | 161 (60) | .77 | 35 (70) | 159 (58) | .11 | 55 (62) | 150 (58) | .45 | 61 (72) | 140 (55) | .008 | 59 (66) | 119 (57) | .15 | 16 (61) | 161 (59) | .82 |
| Sex | |||||||||||||||||||||
| Male | 16 (55) | 202 (63) | .37 | 48 (70) | 163 (61) | .17 | 33 (66) | 169 (61) | .54 | 46 (52) | 172 (66) | .018 | 56 (66) | 155 (61) | .45 | 51 (57) | 136 (65) | .19 | 16 (61) | 169 (62) | .95 |
| Stage | |||||||||||||||||||||
| III, IV | 17 (59) | 167 (53) | .59 | 41 (60) | 139 (53) | .25 | 25 (53) | 145 (53) | .95 | 46 (52) | 138 (54) | .74 | 50 (61) | 130 (52) | .15 | 52 (58) | 110 (53) | .38 | 14 (56) | 147 (54) | .88 |
| LDH | |||||||||||||||||||||
| >ULN | 17 (61) | 148 (51) | .35 | 35 (60) | 126 (50) | .17 | 28 (67) | 127 (49) | .038 | 48 (61) | 117 (49) | .079 | 39 (51) | 122 (53) | .85 | 47 (57) | 96 (49) | .23 | 13 (59) | 129 (51) | .47 |
| ECOG PS | |||||||||||||||||||||
| 2 or more | 12 (41) | 102 (32) | .33 | 22 (32) | 89 (33) | .86 | 17 (36) | 86 (31) | .51 | 35 (40) | 79 (31) | .13 | 27 (33) | 84 (33) | .88 | 36 (40) | 58 (28) | .033 | 9 (36) | 84 (31) | .62 |
| Extranodal sites | |||||||||||||||||||||
| 2 or more | 6 (21) | 50 (16) | .51 | 10 (15) | 42 (16) | .82 | 5 (11) | 45 (16) | .32 | 13 (15) | 43 (17) | .64 | 11 (13) | 41 (16) | .53 | 9 (10) | 37 (18) | .094 | 1 (4) | 45 (17) | .095 |
| IPI score | .22 | .60 | .34 | .40 | .33 | .071 | .86 | ||||||||||||||
| Low (0-1) | 10 (35) | 102 (34) | 19 (29) | 89 (35) | 13 (30) | 95 (36) | 24 (28) | 88 (36) | 24 (30) | 84 (35) | 21 (24) | 77 (38) | 7 (30) | 91 (35) | |||||||
| Intermediate (2-3) | 10 (35) | 143 (48) | 34 (52) | 117 (45) | 19 (43) | 124 (47) | 44 (52) | 109 (45) | 35 (44) | 116 (48) | 47 (54) | 89 (44) | 12 (52) | 122 (46) | |||||||
| High (4-5) | 9 (30) | 56 (19) | 12 (19) | 51 (20) | 12 (27) | 48 (18) | 17 (22) | 48 (19) | 20 (26) | 43 (17) | 19 (22) | 36 (18) | 4 (17) | 51 (19) | |||||||
| Cell of origin* | .088 | .001 | .047 | <.001 | <.001 | <.001 | <.001 | ||||||||||||||
| ABC | 5 (19) | 99 (34) | 11 (17) | 87 (35) | 11 (22) | 92 (35) | 10 (12) | 94 (39) | 46 (58) | 52 (22) | 6 (7) | 89 (43) | 0 | 93 (35) | |||||||
| GCB | 19 (73) | 164 (55) | 48 (74) | 132 (53) | 35 (71) | 142 (53) | 66 (80) | 117 (49) | 24 (30) | 156 (66) | 78 (88) | 98 (47) | 25 (100) | 140 (53) | |||||||
| Unclassified | 2 (8) | 34 (11) | 6 (9) | 30 (12) | 3 (6) | 32 (12) | 7 (8) | 29 (12) | 9 (11) | 27 (12) | 5 (5) | 21 (10) | 0 | 31 (12) | |||||||
| MYC IHC | |||||||||||||||||||||
| Positive | 17 (63) | 117 (39) | .015 | 33 (51) | 98 (39) | .079 | 36 (73) | 96 (36) | <.001 | 30 (37) | 104 (42) | .35 | 44 (54) | 87 (37) | .005 | 38 (44) | 88 (42) | .82 | 20 (80) | 105 (39) | <.001 |
| BCL2 IHC | |||||||||||||||||||||
| Positive | 18 (67) | 199 (67) | .99 | 45 (69) | 164 (65) | .53 | 38 (78) | 172 (64) | .064 | 65 (80) | 152 (62) | .003 | 69 (86) | 140 (59) | <.001 | 80 (91) | 115 (56) | <.001 | 23 (92) | 170 (64) | .004 |
| MYC/BCL2 IHC | |||||||||||||||||||||
| DPE | 15 (56) | 85 (28) | .004 | 23 (35) | 74 (30) | .36 | 30 (61) | 68 (25) | <.001 | 26 (32) | 74 (30) | .70 | 41 (51) | 56 (24) | <.001 | 33 (38) | 61 (30) | .16 | 18 (72) | 75 (28) | <.001 |
Bold indicates significance.
ECOG PS, Eastern Cooperate Oncology Group performance status; Gain/AMP: gain and/or amplification; LDH, lactate dehydrogenase; ULN, upper level of normal.
P value is based on the comparison between the ABC and GCB subtypes.